SITSA UPDATE:

06-20-2018

Kratom Nation:


To those who are anxious to start the grassroots advocacy effort to the U.S. Senate Judiciary Committee on SITSA (H.R. 2851 and S. 1327) please know that AKA, BEA, and KTA are coordinating a broad-based lobbying effort to support the amendment that will protect the legality of kratom.  The AKA, BEA, and KTA lobbying teams are focusing on educating members of the Senate Judiciary Committee on kratom and why SITSA needs to be amended.


The grassroots advocacy is most effective when it occurs right before a hearing and vote is going to be taken.  The offices of Senators and Congressman are inundated every day with calls from constituents, and the overwhelming volume of calls and emails (particularly those that are spread out over a long period of time) literally buries an issue like SITSA – unless we concentrate the calls and emails in the time period immediately before a hearing and vote. A blitz of communications with a consistent message, delivered in a targeted time frame, will be the most effective way to deliver the message that we need to keep kratom legal.


Everyone has the right to express themselves, and we are not suggesting anyone should not do so.  But we strongly urge that we work together to deliver the most powerful message possible at the right time and to the right members of the U.S. Senate.


One last point.  The House of Representatives has passed nearly three dozen opioid crisis bills in the last two weeks, with more to come.  In addition to SITSA, House Bill 5228, the SCREEN Act, also presents some potential risks for consumer access to safe kratom products/plants.  The key issue is the definition of what constitutes an adulterated or misbranded drug.  That is the heart of the SITSA amendment we are supporting where we properly define kratom as a natural plant, not an analogue of an opioid or any other kind of drug or dangerous substance.  We will work on the SCREEN Act as well on this important point.


The AKA fully supports giving the FDA and DEA legitimate tools to interdict dangerous analogues of opioids.  We object to the effort by the FDA to expand the definition of such analogues to a safe plant like kratom.

06-16-2018

On Friday, June 15, 2018, the SITSA Bill passed the floor vote, as expected.  We will be issuing an official Call-To-Action, once it is actually scheduled for the Senate Judiciary Committee.  We are not doing this yet, because we want a very Strong, Concerted, All at one time, effort.

The fight is far from over.

 

SITSA UPDATE:

06-14-2018 11:30 am EST

 

The House Rules Committee voted on party lines, 6-4, to reject the Pocan/Gosar/Polis amendment that would have protected kratom from the SITSA scheduling authority given to the Attorney General.  This was not a vote on the merit of the amendment, but rather a procedural vote by the Republicans to reject ANY amendment that was not discussed or voted on by the Committee of jurisdiction.

 

The SITSA bill was originally assigned to two Committees: The House Judiciary Committee, and the House Energy & Commerce Committee.  When the SITSA bill was marked up by the House Judiciary Committee, the amendment to exempt kratom was not offered because of confusion by Chairman Goodlatte and his staff about the position of the kratom community on SITSA.  A newly formed group at the time had published a statement on their new website supporting SITSA, and the Judiciary Committee staff were directed to that statement by a member of that newly-formed advocacy organization, and they mistakenly believed that statement represented the views of the mainstream kratom community.

 

The House Energy & Commerce Committee intended to debate and accept amendments on SITSA in a Hearing, but that plan was short-circuited by direction by the House Leadership that all "opioid-related" bills would be voted on by Friday of this week, and there was no time to schedule a Hearing on SITSA, so the Committee waived jurisdiction and the SITSA bill was send to the House Rules Committee.

 

The important point for the Kratom Nation to understand is that the vote in the House Rules was not on the merits of the amendment but was actually a procedural maneuver to block a number of other amendments that had not been heard in the Judiciary Committee.

The SITSA bill, when passed by the House on Friday this week as anticipated, will go to the Senate Judiciary Committee where the kratom amendment will be presented and debated.  We will fight hard to have the amendment accepted.

#TeamAKA
#WeAreKratom
#KratomChangesLives

Kratom Nation:
To those who are anxious to start the grassroots advocacy effort to the U.S. Senate Judiciary Committee on SITSA (H.R. 2851 and S. 1327) please know that AKA, BEA, and KTA are coordinating a broad-based lobbying effort to support the amendment that will protect the legality of kratom.  The AKA, BEA, and KTA lobbying teams are focusing on educating members of the Senate Judiciary Committee on kratom and why SITSA needs to be amended.
The grassroots advocacy is most effective when it occurs right before a hearing and vote is going to be taken.  The offices of Senators and Congressman are inundated every day with calls from constituents, and the overwhelming volume of calls and emails (particularly those that are spread out over a long period of time) literally buries an issue like SITSA – unless we concentrate the calls and emails in the time period immediately before a hearing and vote. A blitz of communications with a consistent message, delivered in a targeted time frame, will be the most effective way to deliver the message that we need to keep kratom legal.
Everyone has the right to express themselves, and we are not suggesting anyone should not do so.  But we strongly urge that we work together to deliver the most powerful message possible at the right time and to the right members of the U.S. Senate.
One last point.  The House of Representatives has passed nearly three dozen opioid crisis bills in the last two weeks, with more to come.  In addition to SITSA, House Bill 5228, the SCREEN Act, also presents some potential risks for consumer access to safe kratom products/plants.  The key issue is the definition of what constitutes an adulterated or misbranded drug.  That is the heart of the SITSA amendment we are supporting where we properly define kratom as a natural plant, not an analogue of an opioid or any other kind of drug or dangerous substance.  We will work on the SCREEN Act as well on this important point.
The AKA fully supports giving the FDA and DEA legitimate tools to interdict dangerous analogues of opioids.  We object to the effort by the FDA to expand the definition of such analogues to a safe plant like kratom.

CONTACT US

CALL- 804-552-1252 or EMAIL:

support@americankratom.org

At this time we can not recommend vendors.   Please join a support group on FaceBook or Reddit for help with vendors and general kratom questions.

SUBSCRIBE FOR EMAILS
  • bMJrtC9n
  • Facebook Social Icon
  • Twitter Social Icon
  • YouTube Social  Icon